Today: 20 March 2026
Subscribe
Browse Category

NYSE:DOCN 5 November 2025 - 19 January 2026

Cloud computing stocks face Tuesday test after Trump tariff threat rattles big tech

Cloud computing stocks face Tuesday test after Trump tariff threat rattles big tech

Cloud-focused ETFs fell Friday, with CLOU down 1.34% to $21.34, WCLD off 2.05%, and SKYY losing 0.9%, after U.S. tariff threats and declines in European tech stocks. Nasdaq 100 futures dropped as U.S. markets stayed closed for Martin Luther King Jr. Day. Microsoft reports earnings Jan. 28, Alphabet on Feb. 4. Investors await updates on cloud demand and spending.
19 January 2026
········
DigitalOcean Stock in December 2025: AI Pivot, Earnings Beat and What Comes Next for DOCN

DigitalOcean Stock in December 2025: AI Pivot, Earnings Beat and What Comes Next for DOCN

DigitalOcean shares closed at $48.30 on December 5, 2025, near a 52-week high, valuing the company at about $4.4 billion. Q3 revenue rose 16% to $230 million, with net income boosted by a tax benefit and debt retirement. AI revenue more than doubled year-over-year for the fifth straight quarter. Institutional ownership increased slightly, while options data shows a bullish tilt.
8 December 2025
···
DigitalOcean Stock Skyrockets on AI Momentum and Earnings Beat – What’s Next for DOCN?

DigitalOcean Stock Skyrockets on AI Momentum and Earnings Beat – What’s Next for DOCN?

DigitalOcean shares jumped over 15% to the mid-$45 range in early trading Nov. 5 after Q3 results beat estimates and full-year guidance was raised. Q3 revenue rose 16% to $230 million, with adjusted EPS of $0.54. Large-customer revenue climbed 41% year-over-year. Management now expects 2025 revenue of $896–$897 million, about 16% growth.
5 November 2025
····

Stock Market Today

  • Kessler Topaz Meltzer & Check Files Securities Fraud Class Action Against Soleno Therapeutics
    March 20, 2026, 1:23 PM EDT. Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO) concerning purchases of SLNO stock between March 26 and November 4, 2025. The lawsuit alleges that Soleno made materially false statements and omissions about safety concerns in its Phase 3 clinical trial for diazoxide choline extended-release tablets used to treat hyperphagia linked to Prader-Willi syndrome. The firm claims the company concealed issues relating to excess fluid retention in trial participants. Investors have until May 5, 2026, to seek lead plaintiff status. The complaint is pending in the U.S. District Court for the Northern District of California under case number 3:26-cv-01979. Investors who suffered losses are urged to contact the law firm for legal options at no cost.
Go toTop